Add to ORKGCombination immunotherapy with antibodies directed against PD-1 and CTLA-4 shows improved clinical benefit across cancer indications compared to single agents, albeit with increased toxicity. Leveraging the observation that PD-1 and CTLA-4 are co-expressed by tumor-infiltrating lymphocytes, an investigational PD-1 x CTLA-4 bispecific DART molecule, MGD019, is engineered to maximize checkpoint blockade in the tumor microenvironment via enhanced CTLA-4 blockade in a PD-1-binding-dependent manner
The immune checkpoint cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is an inhibitory regulato...
Targeting immune evasion via immune checkpoint pathways has changed the treatment paradigm in cancer...
The development of immune checkpoint blockers, primarily comprising the anti-PD-1/anti-PD-L1 and ant...
Combination immunotherapy with antibodies directed against PD-1 and CTLA-4 shows improved clinical b...
Combination immunotherapy with antibodies directed against PD-1 and CTLA-4 shows improved clinical b...
Background MGD019 is a bispecific, Fc-bearing (IgG4) DART molecule that blocks PD-1 and CTLA-4, with...
AbstractCancers can be recognized by the immune system, and the immune system may regulate and even ...
The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is co...
The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is co...
The role of immune checkpoints in modulating the magnitude as well as the functional profile of T ce...
The role of immune checkpoints in modulating the magnitude as well as the functional profile of T ce...
We have recently reported that the PD-1 and CTLA4 signaling pathways are active in both effector and...
We have recently reported that the PD-1 and CTLA4 signaling pathways are active in both effector and...
CTLA-4 is a co-receptor on T-cells that controls peripheral tolerance and the development of autoimm...
AbstractCancers can be recognized by the immune system, and the immune system may regulate and even ...
The immune checkpoint cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is an inhibitory regulato...
Targeting immune evasion via immune checkpoint pathways has changed the treatment paradigm in cancer...
The development of immune checkpoint blockers, primarily comprising the anti-PD-1/anti-PD-L1 and ant...
Combination immunotherapy with antibodies directed against PD-1 and CTLA-4 shows improved clinical b...
Combination immunotherapy with antibodies directed against PD-1 and CTLA-4 shows improved clinical b...
Background MGD019 is a bispecific, Fc-bearing (IgG4) DART molecule that blocks PD-1 and CTLA-4, with...
AbstractCancers can be recognized by the immune system, and the immune system may regulate and even ...
The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is co...
The clinical benefit of PD-1 blockade can be improved by combination with CTLA4 inhibition but is co...
The role of immune checkpoints in modulating the magnitude as well as the functional profile of T ce...
The role of immune checkpoints in modulating the magnitude as well as the functional profile of T ce...
We have recently reported that the PD-1 and CTLA4 signaling pathways are active in both effector and...
We have recently reported that the PD-1 and CTLA4 signaling pathways are active in both effector and...
CTLA-4 is a co-receptor on T-cells that controls peripheral tolerance and the development of autoimm...
AbstractCancers can be recognized by the immune system, and the immune system may regulate and even ...
The immune checkpoint cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is an inhibitory regulato...
Targeting immune evasion via immune checkpoint pathways has changed the treatment paradigm in cancer...
The development of immune checkpoint blockers, primarily comprising the anti-PD-1/anti-PD-L1 and ant...